Duodenal Ulcer Treatment Market (2025 - 2030)

Duodenal Ulcer Treatment Market Trends

The global duodenal ulcer treatment market size was estimated at USD 4.59 billion in 2024 and is anticipated to grow at a CAGR of 3.2% from 2025 to 2030. The rising occurrence of duodenal ulcers is largely attributed to factors such as stress, unhealthy eating habits, smoking, excessive alcohol consumption, and infections caused by Helicobacter pylori. These factors contribute to the growing number of people affected by this condition. As a result, there is an increasing demand for effective treatment options. The need for medications and therapies to manage and heal duodenal ulcers has led to advancements in the healthcare sector. This growing demand is significantly driving the growth of the duodenal ulcer treatment industry.

Advancements in treatment options are significantly shaping the growth of the duodenal ulcer treatment industry. Ongoing research has led to the development of new medications, such as Proton Pump Inhibitors (PPIs), which help reduce stomach acid and promote healing. In addition, therapies targeting Helicobacter pylori, a common cause of duodenal ulcers, are improving treatment outcomes. New drug classes are also being introduced, giving doctors more choices to treat the condition effectively. These innovations enhance the overall management of duodenal ulcers and improve patient recovery. Hence, advancements in treatment options are crucial in expanding the duodenal ulcer treatment industry.

In addition, awareness and improvements in diagnosis play an important role in the growth of the duodenal ulcer treatment industry. As more people became aware of the symptoms and risks associated with duodenal ulcers, they sought medical help earlier. Early diagnosis improves the chances of successful treatment and reduces the risk of complications. As awareness continues to rise, more patients are being treated, which increases the demand for effective therapies. These factors are driving the growth of the duodenal ulcer treatment industry.

Treatment Insights

The proton pump inhibitors segment dominated the market with a revenue share of 52.1% in 2024, driven by the increasing prevalence of gastrointestinal disorders, particularly among the aging population, who are more susceptible to conditions such as duodenal ulcers. Furthermore, increased awareness regarding effective treatment options has led to greater adoption of PPIs, as they are recognized for their efficacy in reducing stomach acid and promoting ulcer healing. The robust pipeline of novel drug candidates also contributes to sustained interest and investment in this therapeutic area.

The antibiotics segment is projected to grow at the highest CAGR of 4.0% over the forecast period, fueled by the rising incidence of Helicobacter pylori infections, a primary cause of duodenal ulcers. As healthcare providers increasingly recognize the importance of eradicating these infections as part of ulcer management, the demand for effective antibiotic regimens has surged. In addition, advancements in antibiotic formulations and delivery methods enhance treatment outcomes, further driving market expansion.

Route of Administration Insights

The oral segment dominated the market with the largest revenue share in 2024, driven by patient preference for non-invasive treatment options that offer ease of administration and convenience. Oral medications, including PPIs and antibiotics, are often preferred due to their effectiveness and the ability to self-administer them at home. The growing awareness about gastrointestinal health has also encouraged patients to seek oral treatment as a first-line approach for managing duodenal ulcers.

The parenteral segment is predicted to grow at a significant CAGR over the forecast period due to its critical role in treating patients with severe or complicated cases of duodenal ulcers. Parenteral administration allows for rapid delivery of medications directly into the bloodstream, which can be essential for patients who are unable to take oral medications due to nausea or other complications. For instance, parenteral nutrition can be delivered either as a continuous infusion over 24 hours or as a cyclic infusion, typically lasting 8 to 12 hours. The increasing prevalence of severe gastrointestinal conditions necessitates effective parenteral therapies, thereby driving growth in this segment.

End-use Insights

The retail pharmacies segment dominated the market with the largest revenue share in 2024, fueled by the accessibility and convenience that retail pharmacies provide for patients seeking over-the-counter medications for duodenal ulcers. With a growing emphasis on self-care and preventive health measures, more patients are turning to retail pharmacies for their treatment needs. Moreover, competitive pricing and promotions offered by these pharmacies enhance their appeal among consumers

The hospital pharmacies segment is projected to grow at the significant CAGR over the forecast period, which can be attributed to their essential role in managing acute cases of duodenal ulcers requiring immediate medical attention. Hospital pharmacies have direct access to patients who need specialized care and complex medication regimens. The presence of healthcare professionals ensures appropriate dosing and adherence to treatment protocols, which is critical for successful outcomes in severe cases

Regional Insights

North America duodenal ulcer treatment market held the highest revenue share of 39.5% in 2024, fueled by the advanced healthcare infrastructure and high levels of healthcare spending among consumers. The region's focus on preventive healthcare and early diagnosis also contributes significantly to market growth. Moreover, the presence of major pharmaceutical companies enhances research and development efforts aimed at improving treatment options.

U.S. Duodenal Ulcer Treatment Market Trends

The U.S. duodenal ulcer treatment market dominated North America with the highest revenue share in 2024, which can be attributed to high patient awareness regarding gastrointestinal health issues and its well-established healthcare system. The widespread availability of effective treatments through prescription and over-the-counter options facilitates patient access to necessary medications, leading to better management of duodenal ulcers.

Europe Duodenal Ulcer Treatment Market Trends

Europe duodenal ulcer treatment market held a substantial market share in 2024, driven by increasing awareness about gastrointestinal disorders and advancements in medical treatments available across various European countries. Integrating innovative therapies into clinical practice enhances treatment efficacy and patient outcomes, contributing to steady market growth within Europe.

Asia Pacific Duodenal Ulcer Treatment Market Trends

Asia Pacific duodenal ulcer treatment market is expected to register the highest CAGR of 3.8% over the forecast period, which can be attributed to rising healthcare expenditures and an increase in the prevalence of gastrointestinal disorders among its population. Growing urbanization and lifestyle changes are contributing factors that lead to higher incidences of conditions such as duodenal ulcers, thereby driving demand for effective treatments in Asia Pacific.

China duodenal ulcer treatment market dominated the Asia Pacific with a significant revenue share in 2024 due to its large population facing increasing rates of gastrointestinal diseases. Enhanced healthcare investments and improved access to modern medical facilities facilitate better patient diagnosis and treatment options. Furthermore, the Chinese government's focus on research and development in gastrointestinal therapies is expected to stimulate market growth, leading to the introduction of innovative treatment options.

Key Duodenal Ulcer Treatment Company Insights

Some key companies operating in the market are GSK plc.; Pfizer Inc.; Novartis AG; Merck KGaA, and NIHON GENERIC Co., Ltd. Companies are undertaking strategic initiatives, such as mergers, acquisitions, and product launches, to expand their market presence and address the evolving healthcare demands in duodenal ulcer treatment market.

• GSK plc offers a variety of products for treating duodenal ulcers, emphasizing effective pharmacological treatments. Its portfolio includes Proton Pump Inhibitors (PPIs) such as omeprazole and lansoprazole, which help reduce gastric acid and promote healing of ulcers. The Company also provides antibiotics that work with PPIs to eliminate Helicobacter pylori, a common cause of these ulcers. In addition, they offer H2-receptor antagonists for acid reduction and sucralfate, which protects ulcer sites to aid healing. Through ongoing research and innovation, it aims to improve treatment effectiveness and patient outcomes for those suffering from duodenal ulcers.

• Pfizer Inc. provides various products for treating duodenal ulcers, focusing on effective pharmacological solutions. Its key offerings include Famotidine, an H2-receptor antagonist that helps reduce gastric acid secretion and support ulcer healing in both oral and injectable forms. The company also offers Cytotec (misoprostol) to treat duodenal ulcers and prevent NSAID-induced ulcers by enhancing mucosal protection. In addition, it supplies Rabeprazole, a proton pump inhibitor that effectively suppresses acid production to treat active duodenal ulcers.

Recent Developments

• In January 2025, GSK agreed to acquire IDRx, Inc. This acquisition is intended to enhance its portfolio of innovative therapeutics. By integrating IDRx’s expertise and pipeline, the company sought to accelerate its research and development efforts, ultimately aiming to deliver new treatment options to patients.

• In April 2024, Novartis announced that the U.S. Food and Drug Administration (FDA) approved Lutathera for the treatment of pediatric patients aged 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This approval marked a significant milestone as Lutathera became the first therapy specifically approved for children with this rare form of cancer. The decision was based on the NETTER-P trial, which showed a consistent safety profile and similar drug exposure between pediatric and adult patients.

Duodenal Ulcer Treatment Market